20.46 0.41 (2.04%) | 07-18 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 24.82 ![]() |
1-year : | 28.99 ![]() |
Resists | First : | 21.25 ![]() |
Second : | 24.82 ![]() |
Pivot price | 19.84 ![]() |
|||
Supports | First : | 19.55 ![]() |
Second : | 18.5 |
MAs | MA(5) : | 20.19 ![]() |
MA(20) : | 19.71 ![]() |
MA(100) : | 18.52 ![]() |
MA(250) : | 18.09 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 54.1 ![]() |
D(3) : | 52.3 ![]() |
RSI | RSI(14): 55.5 ![]() |
|||
52-week | High : | 22.5 | Low : | 14.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MDWD ] has closed below upper band by 24.7%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 21.05 - 21.13 | 21.13 - 21.22 |
Low: | 19.88 - 19.97 | 19.97 - 20.07 |
Close: | 20.3 - 20.44 | 20.44 - 20.6 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Mon, 30 Jun 2025
MediWound Ltd.(NasdaqGM: MDWD) added to Russell Small Cap Comp Value Index - MarketScreener
Wed, 21 May 2025
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Fri, 21 Mar 2025
MediWound Ltd (MDWD) Q4 2024 Earnings Report Preview: What To Lo - GuruFocus
Thu, 20 Mar 2025
MediWound Ltd (MDWD) Q4 2024 Earnings Call Highlights: Revenue G - GuruFocus
Wed, 19 Mar 2025
MediWound Reports 2024 Financials and Strategic Advances - TipRanks
Wed, 19 Mar 2025
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 11 (M) |
Shares Float | 8 (M) |
Held by Insiders | 17.9 (%) |
Held by Institutions | 43.5 (%) |
Shares Short | 917 (K) |
Shares Short P.Month | 962 (K) |
EPS | -2.05 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.9 |
Profit Margin | -110.5 % |
Operating Margin | -132.2 % |
Return on Assets (ttm) | -19.9 % |
Return on Equity (ttm) | -78 % |
Qtrly Rev. Growth | -20.3 % |
Gross Profit (p.s.) | 0.25 |
Sales Per Share | 1.77 |
EBITDA (p.s.) | -1.86 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -13 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -9.99 |
PEG Ratio | 0 |
Price to Book value | 7.05 |
Price to Sales | 11.51 |
Price to Cash Flow | -16.85 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |